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symptom control; improvement in respirato‑
ry function; reduction in exacerbation rate; 
improvement in quality of life; healthcare 
cost control. All these outcomes should be 
checked over a long‑term period in order to 
assess their absolute value both in clinical 
and economic terms.
Despite the wide consensus concerning 
COPD as a progressive disease, the conve‑
nience of therapy has been mainly focused 
in the most severe stages of COPD (GOLD 
stages 3 and 4), while the hypothesis that 
current therapeutic options might also be ef‑
fective in earlier stages of COPD and might 
INTRODUCTION
Chronic Obstructive Pulmonary Disease 
(COPD) represents a pathological condition 
of the respiratory system which maximal‑
ly prevails since the 5th decade of life: it is 
only partially reversible, and can progressi‑
vely affect both lung structures and function. 
COPD is one of the most common causes of 
morbidity and mortality worldwide, and it is 
characterized by a very high socio‑economic 
impact, particularly for health systems of in‑
dustrialized countries [1‑3].
The governance of the disease is based on a 
complex strategy, such as: stopping smoking; 
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ABSTRACT
BACKGROUND: Tiotropium monotherapy enables a significant minimization of morbidity in COPD. OBJECTIVE: to 
evaluate and compare cost and cost‑effectiveness of tiotropium monotherapy administrated for 24 months (18 μg od) in 
mild‑to‑moderate and severe chronic obstructive pulmonary disease (COPD). METHODS: Clinical outcomes (days in 
hospital; visits in general ward; cycles of systemic steroids; cycles of antibiotics and maintenance therapy drugs) were 
evaluated in two groups of patients corresponding to predicted FEV1 baseline values ≤ 50% (A) and > 50% (B) from 
the Italian NHS perspective. In order to perform cost‑effectiveness analysis, FEV1 value, available for each patient, was 
converted in SGRQ score using a published multivariate linear model. Utilities were then obtained through the Ståhl equa‑
tion. RESULTS: The comparison between 24 months of standard therapy and subsequent 24‑month period of tiotropium 
monotherapy showed that hospitalization cost, which represents the driving treatment cost, drops from 77% to 69% (A) 
and from 67% to 33% (B) of the total cost. Differently, maintenance therapy cost increased but the amount was more than 
offset by the savings accruing from the shortening of hospitalization. Furthermore, cost‑effectiveness results revealed a 
mean savings of about 216 € (A) and 961 € (B) other than a mean gain of 0.07 QALY (A) and 0.02 QALY (B). Dominance 
of tiotropium (calculated only within patients completing treatment course) revealed that in almost 29% (A) and 36% (B) 
of subjects tiotropium strategy is dominant while only in 2% (A) and 7% (B) of cases is associated to costs increment 
and worsening on quality of life. The dominance was systematic in severe COPD. Statistical analyses confirm such trend. 
CONCLUSIONS: Results of the present study suggest that tiotropium used as unique treatment in COPD systematically 
consents significant costs savings together with positive effects on evaluated quality. These effects prove proportional to 
COPD severity.
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failure (RF) [11] weighted for the frequency 
reported for each year. Visits to general prac‑
titioner (GP) was taken from Garattini et 
al. [12] and actualized to 2013 [13]. Drugs 
consumption (maintenance and exacerba‑
tion management drugs) was measured and 
valued [14] in terms of prescribed packages, 
furthermore discount applied by pharmacies 
was considered in the cost evaluation. Cost 
for one cycle of antibiotics and yearly main‑
tenance therapy cost (both for CT and MT) 
are detailed in Table II and Table III. FEV1 
values, available at several time points for 
each patient, were converted in SGRQ scores 
using a published multivariate linear model 
[15], then utilities were obtained through the 
Ståhl equation [16].
Difference between CT and MT in both 
groups were tested using Welch test (for con‑
tinuous variables) and chi‑squared test (for 
dichotomous variables). All analyses were 
performed using the statistical software R. 
Also the cost‑effectiveness of tiotropium 
monotherapy was inferred from the sample 
analysis [17] and presented in terms of con‑
fidence ellipses and probabilistic cost‑effecti‑
veness acceptability curves (CEAC).
RESULTS
The whole sample consisted of 319 COPD 
subjects: Group A (154 severe COPD pa‑
tients; 104 males, mean ± SEM age = 72.1 
± 0.51 years; FEV1% pred. = 45.4 ± 0.61; 
FVC % pred. = 63.6 ± 0.48), and group B 
(165 mild‑to‑moderate COPD patients, 111 
males, mean ± SEM age = 71.4 ± 0.60 ye‑
ars; FEV1 % pred. = 65.5. ± 5.7 ; FVC % 
pred. = 64.7 ± 0.85. The two groups proved 
homogeneous in terms of distribution by 
gender, age, and use of systemic steroids; 
they were obviously significantly different 
only in terms of basal lung function, and of 
morbidity of the disease [10].
Total cost per patient per year is detailed in 
Table IV. Results from comparison between 
24 months of CT and subsequent 24 months 
of MT showed that hospitalization cost, 
which represents the main cost driver, drop‑
ped from 77% to 69% (A), and from 66% to 
33% (B), of the total cost, (Figure 1). Con‑
versely, maintenance therapy cost increased 
but this amount was more than offset by the 
savings accruing from the shortening of ho‑
spitalization (Figure 1). The re‑distribution 
of cost composition resulted statistical signi‑
ficant in both groups: p=0.03 (A), p<0.0001 
(B).
Furthermore, cost‑effectiveness results (Ta‑
ble V) revealed a mean savings of more than 
216 € (p=0.63) in the Group A, and 961 € 
Antibiotics Package
Unit 
cost (€)
Packages 
per cycle (n°)
Cost  
per Cycle (€)
Composition 
(%)
Ceftazidime 1 g powder for solution for injection,10 vials 48.31 3 144.92
154.75
25
1 g/3ml monovial 5.49 30 164.59
Moxifloxacin 400 mg 5 film‑coated tablets 20.86 2 41.71 20
Ciprofloxacin 500 mg 6 film‑coated tablets 6.54 4 26.14 20
Amoxifloxacin+ 
clavulanic acid
875 mg + 125 mg 12 film‑coated tablets 9.82 3 29.45
29.45
35
875 mg + 125 mg powder for oral 
suspension, 12 sachets
9.82 3 29.45
Mean cost for one cycle of antibiotics (€) 62.57
Table II. Detailed composition of one cycle of antibiotics
Drugs
Cost per 
package 
(€)
Packages 
per year 
(n°)
Therapy composition (%)
CT TM
Fluticasone/
salmeterol
68.79 6 30 ‑
Budesonide/
formoterol
59.51 12 35 ‑
Beclomethasone/
formoterol
49.22 4 3 ‑
Theo‑dur 3.14 24 20 ‑
Tiotropium 47.75 13 9 100
Mean cost for one year of maintenance 
therapy (€)
449.82 620.78
Table III. Detailed composition of maintenance therapy prior to tiotropium 
monotherapy
Year 1 Year 2 Year 3 Year 4
Group A (FEV1≤50%)
N patients 154 142 133 129
Unitary costs (€)
 • Hospital stays 1,664.81 2,035.04 1,700.21 1,371.55
 • GP visits 20.26 17.88 12.48 16.21
 • Steroids 3.79 3.50 2.80 2.89
 • Antibiotics 107.67 84.60 71.98 61.60
 • Maintenance therapy 449.82 449.82 620.78 620.78
Total cost (€) 2,246.35 2,590.84 2,408.25 2,073.03
Group B (FEV1>50%)
N patients 165 159 140 126
Unitary costs (€)
 • Hospital stays 705.10 1,189.02 309.42 327.02
 • GP visits 10.86 8.39 4.36 5.40
 • Steroids 1.73 1.95 2.03 3.35
 • Antibiotics 8.72 26.37 22.63 18.37
 • Maintenance therapy 449.82 449.82 620.78 620.78
Total cost (€) 1,176.23 1,676.55 959.21 974.92
Table IV. Annual management cost per COPD patient resulted from the cost 
analysis
Figure 1. Detailed costs for group A and group B patients: comparison 
between current therapy and tiotropium monotherapy
particularly after the post‑hoc and secondary 
analyses carried out within these large stu‑
dies [5‑9].
A recent observational study compared the 
effects of current therapeutic options with tio‑
tropium bromide monotherapy administrated 
for 24 months (18 μg od) in patients suffering 
from mild‑to‑moderate and severe COPD 
[10]. The study showed that tiotropium mo‑
notherapy enables a significant minimization 
of morbidity in two groups of COPD patients 
corresponding to predicted FEV1 baseline 
values ≤ 50% and > 50%m respectively [10].
Data collected in this study were used with 
the aim of performing and comparing cost 
and cost‑effectiveness analyses for tiotro‑
pium monotherapy (18 μg od) administrated 
over a 24‑month period in patients suffering 
from mild‑to‑moderate and severe chronic 
obstructive pulmonary disease (COPD) from 
the Italian National Health System (NHS) 
perspective.
METHODS
Dataset used in the analysis was automatical‑
ly extracted from the central Database accor‑
ding to the procedure already analytically de‑
scribed in a previous paper [10]. The division 
of subjects into two groups according to their 
FEV1 basal value > or > 50% predicted was 
maintained.
All subjects were followed for 4 years: the 
outcomes of the 24 months of current therapy 
(CT) preceding the index date were com‑
pared to those obtained with regular mono‑
therapy tiotropium 18 μg daily (MT) for the 
subsequent two years.
Economic value of clinical outcomes are re‑
ported in Table I. 
Hospital cost was evaluated as the mean cost 
of ICU and hospital admissions for COPD 
exacerbation and chronic/acute respiratory 
Outcomes Cost (€) Notes
Hospital stay
ICU stay 3,565 DRG 565
Chronic/acute RF 3,565 DRG 87
COPD exacerbation 2,424 DRG 88
GP visit 16.60 One GP visit
Systemic steroids 12.43 One cycle of systemic steroids
Antibiotics 62.57 One cycle of antibiotics
Maintenance therapy
First 24 months of analysis 449.82 Annual main therapy 
(ICS+LABA, LAMA, MTX)
Subsequent 24 months 620.78 Annual tiotropium monotherapy
Table I. Unit cost of clinical outcomes exploited in the analyses
GP: general practitioner, ICS: inhaled corticosteroids, LABA: long‑acting beta‑agonists, 
LAMA: long‑acting muscarinic antagonists, MTX: methylxanthines; RF: respiratory failure
be able to influence the disease progression 
was almost completely neglected up to a re‑
cent past. Actually, the hypothesis that also 
the earlier treatment of COPD might be use‑
ful and convenient was accepted only after 
the suggestions emerged from the two most 
important international long‑term clinical 
trials published in the last years [3,4], and 
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(p<0.0001) in the Group B, alongside a mean 
gain of 0.07 ( p<0.001), and 0.02 QALY 
(p=0.53), respectively. One‑side Welch test 
performed on non‑significant results estimate 
that total cost per patients of MT can exceed 
CT at most of 516 € (A) while the loss of 
QALY is not greater than 0.03 (B), p<0.05 
for both analyses.
failure (RF) [11] weighted for the frequency 
reported for each year. Visits to general prac‑
titioner (GP) was taken from Garattini et 
al. [12] and actualized to 2013 [13]. Drugs 
consumption (maintenance and exacerba‑
tion management drugs) was measured and 
valued [14] in terms of prescribed packages, 
furthermore discount applied by pharmacies 
was considered in the cost evaluation. Cost 
for one cycle of antibiotics and yearly main‑
tenance therapy cost (both for CT and MT) 
are detailed in Table II and Table III. FEV1 
values, available at several time points for 
each patient, were converted in SGRQ scores 
using a published multivariate linear model 
[15], then utilities were obtained through the 
Ståhl equation [16].
Difference between CT and MT in both 
groups were tested using Welch test (for con‑
tinuous variables) and chi‑squared test (for 
dichotomous variables). All analyses were 
performed using the statistical software R. 
Also the cost‑effectiveness of tiotropium 
monotherapy was inferred from the sample 
analysis [17] and presented in terms of con‑
fidence ellipses and probabilistic cost‑effecti‑
veness acceptability curves (CEAC).
RESULTS
The whole sample consisted of 319 COPD 
subjects: Group A (154 severe COPD pa‑
tients; 104 males, mean ± SEM age = 72.1 
± 0.51 years; FEV1% pred. = 45.4 ± 0.61; 
FVC % pred. = 63.6 ± 0.48), and group B 
(165 mild‑to‑moderate COPD patients, 111 
males, mean ± SEM age = 71.4 ± 0.60 ye‑
ars; FEV1 % pred. = 65.5. ± 5.7 ; FVC % 
pred. = 64.7 ± 0.85. The two groups proved 
homogeneous in terms of distribution by 
gender, age, and use of systemic steroids; 
they were obviously significantly different 
only in terms of basal lung function, and of 
morbidity of the disease [10].
Total cost per patient per year is detailed in 
Table IV. Results from comparison between 
24 months of CT and subsequent 24 months 
of MT showed that hospitalization cost, 
which represents the main cost driver, drop‑
ped from 77% to 69% (A), and from 66% to 
33% (B), of the total cost, (Figure 1). Con‑
versely, maintenance therapy cost increased 
but this amount was more than offset by the 
savings accruing from the shortening of ho‑
spitalization (Figure 1). The re‑distribution 
of cost composition resulted statistical signi‑
ficant in both groups: p=0.03 (A), p<0.0001 
(B).
Furthermore, cost‑effectiveness results (Ta‑
ble V) revealed a mean savings of more than 
216 € (p=0.63) in the Group A, and 961 € 
Antibiotics Package
Unit 
cost (€)
Packages 
per cycle (n°)
Cost  
per Cycle (€)
Composition 
(%)
Ceftazidime 1 g powder for solution for injection,10 vials 48.31 3 144.92
154.75
25
1 g/3ml monovial 5.49 30 164.59
Moxifloxacin 400 mg 5 film‑coated tablets 20.86 2 41.71 20
Ciprofloxacin 500 mg 6 film‑coated tablets 6.54 4 26.14 20
Amoxifloxacin+ 
clavulanic acid
875 mg + 125 mg 12 film‑coated tablets 9.82 3 29.45
29.45
35
875 mg + 125 mg powder for oral 
suspension, 12 sachets
9.82 3 29.45
Mean cost for one cycle of antibiotics (€) 62.57
Table II. Detailed composition of one cycle of antibiotics
Drugs
Cost per 
package 
(€)
Packages 
per year 
(n°)
Therapy composition (%)
CT TM
Fluticasone/
salmeterol
68.79 6 30 ‑
Budesonide/
formoterol
59.51 12 35 ‑
Beclomethasone/
formoterol
49.22 4 3 ‑
Theo‑dur 3.14 24 20 ‑
Tiotropium 47.75 13 9 100
Mean cost for one year of maintenance 
therapy (€)
449.82 620.78
Table III. Detailed composition of maintenance therapy prior to tiotropium 
monotherapy
Year 1 Year 2 Year 3 Year 4
Group A (FEV1≤50%)
N patients 154 142 133 129
Unitary costs (€)
 • Hospital stays 1,664.81 2,035.04 1,700.21 1,371.55
 • GP visits 20.26 17.88 12.48 16.21
 • Steroids 3.79 3.50 2.80 2.89
 • Antibiotics 107.67 84.60 71.98 61.60
 • Maintenance therapy 449.82 449.82 620.78 620.78
Total cost (€) 2,246.35 2,590.84 2,408.25 2,073.03
Group B (FEV1>50%)
N patients 165 159 140 126
Unitary costs (€)
 • Hospital stays 705.10 1,189.02 309.42 327.02
 • GP visits 10.86 8.39 4.36 5.40
 • Steroids 1.73 1.95 2.03 3.35
 • Antibiotics 8.72 26.37 22.63 18.37
 • Maintenance therapy 449.82 449.82 620.78 620.78
Total cost (€) 1,176.23 1,676.55 959.21 974.92
Table IV. Annual management cost per COPD patient resulted from the cost 
analysis
Figure 1. Detailed costs for group A and group B patients: comparison 
between current therapy and tiotropium monotherapy
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while only in 2% (A) and 7% (B) of cases an 
increase in costs was associated with a wor‑
sening of quality of life. Statistical analyses 
show that for severe COPD patients (A) MT 
strategy was more effective for any confi‑
dence level (Figure 2) and cost‑effective for 
willingness‑to‑pay values of at least 10,000 € 
(Figure 3).
For mild‑to‑moderate COPD patients (B) MT 
strategy was less expensive for any confiden‑
ce level (Figure 4): CEAC did not asymptote 
to 1 since there is a 20% of probability that 
MT strategy does not involve health gains 
(Figure 5).
DISCUSSION
Data from the present investigation lead to 
several considerations. Firstly, COPD pa‑
tients referring for the first time to a Specia‑
list Centre usually show a disease condition 
which is already characterized by a relevant 
clinical and a pharmacoeconomic impact; 
secondly, this impact is not merely depen‑
dent of their limitation in lung function. Ac‑
tually, subjects suffering from mild‑to‑mo‑
derate COPD showed an unexpectedly 
remarkable impact. Moreover, the home 
therapy followed over the last 12 months 
before the first visit to the Centre (such as 
in the period year ‑1 vs. year 0 values) did 
not produce any substantial improvement of 
clinical and pharmacoeconomic variables, 
independently of the severity of their lung 
function impairment.
The switch to tiotropium 18 μg od mono‑
therapy on a regular basis consented a pro‑
gressively and substantial improvement of 
economic variables, and this strategy proved 
highly effective and the most convenient par‑
ticularly in most severe patients (Group A)
Figure 2. Confidence ellipses for different significant levels (MT vs. CT) in 
FEV1≤50% patients (A)
Figure 3. Cost-effectiveness acceptability curve (MT vs. CT) for FEV1≤50% patients (A)
Figure 4. Confidence ellipses for different significant levels (MT vs. CT) in 
FEV1>50% patients (B)
Figure 5. Cost-effectiveness acceptability curve (MT vs. CT) for FEV1>50% patients (B)
Among patients completing treatment course, 
MT strategy was observed to be dominant 
in almost 30% (A) and 36% (B) of subjects 
24 months 
CT
24 months 
MT
Difference p‑value
Group A (FEV1≤50%)
Total cost (SEM) € 4,635  
(307)
€ 4,419 
(320)
€ ‑216  
(257)
0.63
QALY (SEM) 1.20  
(0.014)
0.27  
(0.011)
0.07  
(0,010)
<0.001
Group B (FEV1>50%)
Total cost (SEM) € 2,791  
(165)
€ 1,830  
(113)
€ ‑961  
(195)
<0.0001
QALY (SEM) 1.54  
(0.015)
1.56 
 (0.024)
0.02  
(0.022)
0.53
Table V. Cost-effectiveness results: first 24 months od current therapy (CT) vs 
last 24 months of tiotropium monotherapy (MT)
SEM = Standard Error Mean
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in severe and in mild‑to‑moderate patients in 
our sample, and resulted cost‑effective. Stati‑
stical analysis confirms the reliability of the‑
se results particularly in severe COPD, being 
the confidence on the cost‑effectiveness in 
mild‑to‑moderate COPD about 80%. It is 
presumable that also in milder conditions this 
strategy would play a critical role in the natu‑
ral history of COPD.
The present study was designed in order to 
also investigate in real life the opportunity 
and the convenience of an earlier therapeutic 
intervention in COPD. Data obtained tend to 
support and emphasize both the utility and 
the convenience of the earlier regular and 
long‑term treatment of COPD, i.e. starting 
when the functional (and presumably also the 
structural damage) is lower. Furthermore, the 
positive trend of pulmonary function coupled 
with the global improvement of pharma‑
co‑economic outcomes is a feature of further 
great value from this point of view.
The introduction of tiotropium as a daily 
therapeutic strategy enables a significant mi‑
nimization of the socio‑economic impact of 
COPD, which proves substantial and syste‑
matic when COPD is severe.
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